ProfileGDS5678 / 1424047_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 81% 81% 83% 84% 82% 78% 82% 82% 81% 82% 81% 81% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0971283
GSM967853U87-EV human glioblastoma xenograft - Control 25.9017781
GSM967854U87-EV human glioblastoma xenograft - Control 35.8605581
GSM967855U87-EV human glioblastoma xenograft - Control 46.1824683
GSM967856U87-EV human glioblastoma xenograft - Control 56.276484
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6811582
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2931478
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8610182
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9453482
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8758981
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.951582
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8758881
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7784981
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9218682